Figure 2.

OHR (A) and MCyR (B) by individual baseline Bcr‐Abl mutations in AP, BP, and ALL cohorts. Individual patients may have had more than one detected mutation. Bosutinib IC₅₀ concentrations were based on data from 34. ^aIncludes one evaluable ALL patient with a F317L mutation who did not achieve a response; ^bincludes one evaluable ALL patient with a G250E mutation who did not achieve a response; ^cincludes one evaluable ALL patient with a E255V mutation who did not achieve a response; ^dincludes three evaluable ALL patients with a T315I mutation who did not achieve a response; ^eincludes one evaluable ALL patient with a F359C mutation who did not achieve a response. Eval, number of patients with each baseline mutation who had a valid baseline efficacy assessment for the respective endpoint; IC₅₀, half‐maximal inhibitory concentration; MCyR, major cytogenetic response; OHR, overall hematologic response.